P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma

P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma

Bibliographic Details
Main Authors:	Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Andreas Engert, Paul J. Bröckelmann, Wolfram Klapper, Michael Altenbuchinger
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000890764.00950.f2

Similar Items

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
by: Berit Müller-Meinhard, et al.
Published: (2022-10-01)

Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma
by: Berit Müller‐Meinhard, et al.
Published: (2024-06-01)

P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
by: Johanna Grund, et al.
Published: (2022-10-01)

Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
by: Stephanie Sasse, et al.
Published: (2019-01-01)

Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment
by: Stephanie Sasse, et al.
Published: (2019-01-01)

Controversies in the Treatment of Classical Hodgkin Lymphoma
by: Dennis A. Eichenauer, et al.
Published: (2018-10-01)

P049 (0072) RESULTS OF CARDIOVASCULAR SCREENING IN THE BETER SURVIVORSHIP CARE INITIATIVE FOR HODGKIN LYMPHOMA
Published: (2018-10-01)

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma
by: Yucai Wang, et al.
Published: (2018-04-01)

Genetics of classical Hodgkin Lymphoma
by: Gianluca Schiavoni, et al.
Published: (2018-06-01)

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
by: Peter Hollander, et al.
Published: (2018-01-01)

S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
by: Jan-Michel Heger, et al.
Published: (2023-08-01)

Composite follicular lymphoma and classic Hodgkin lymphoma
by: Han-Na Kim, et al.
Published: (2022-01-01)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
by: Jesko Momotow, et al.
Published: (2019-10-01)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
by: Ahmet Dogan
Published: (2022-10-01)

Classical Hodgkin’s Lymphoma Presenting as Erythroderma
by: Kumar Parimalam, et al.
Published: (2022-11-01)

Hodgkin-Reed-Sternberg cells in classical Hodgkin lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity.
by: Maciej Giefing, et al.
Published: (2013-01-01)

Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin’s lymphoma by array-based comparative genomic hybridization
by: Sylvia Hartmann, et al.
Published: (2008-09-01)

ETS1 encoding a transcription factor involved in B-cell differentiation is recurrently deleted and down-regulated in classical Hodgkin's lymphoma
by: Birte Malaika Overbeck, et al.
Published: (2012-10-01)

Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist
by: Nicole A. Carreau, et al.
Published: (2019-05-01)

Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma
by: Julian Benckendorff, et al.
Published: (2021-06-01)

High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome
by: Peter Hollander, et al.
Published: (2017-08-01)

Moving things forward in Hodgkin lymphoma [version 1; referees: 2 approved]
by: Paul J. Bröckelmann, et al.
Published: (2018-11-01)

S218: CORRELATION BETWEEN PROGRESSION-FREE AND OVERALL SURVIVAL IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: A COMPREHENSIVE ANALYSIS OF INDIVIDUAL PATIENT DATA FROM RANDOMIZED GHSG TRIALS
by: Paul Bröckelmann, et al.
Published: (2023-08-01)

Evolution of drug therapy for classical Hodgkin lymphoma
by: N. Y. Samaneva, et al.
Published: (2022-09-01)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
by: Mikalai Katsin, et al.
Published: (2023-12-01)

Current directions in the treatment of classical Hodgkin lymphoma
by: Frank G. Keller, et al.
Published: (2023-11-01)

Treatment Of Classical Hodgkin Lymphoma: The State Of The Art
by: Carmino Antonio de Souza, et al.
Published: (2023-10-01)

Bone marrow involvement by classic Hodgkin lymphoma
by: Mohammad Barouqa, et al.
Published: (2022-05-01)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
by: Soyoung Im, et al.
Published: (2022-11-01)

Bob-1 is expressed in classic Hodgkin lymphoma
by: Abd El All Howayda S
Published: (2007-03-01)

Relapsed and refractory classical Hodgkin lymphoma immunotherapy
by: Kirill Lepik
Published: (2020-10-01)

T004 (0051) EXPRESSION OF PD-1 AND PD-L1 INCREASE IN MULTIPLE CONSECUTIVE BIOPSIES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

T006 (0079) THE PERIPHERAL BLOOD NEUTROPHIL PD-L1 AND LYMPHOCYTE PD-1 AXIS IN CLASSICAL HODGKIN LYMPHOMA AT DIAGNOSIS
Published: (2018-10-01)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017-03-01)

T002: Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
by: Peter Borchmann, et al.
Published: (2022-10-01)

Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP
by: Ron Daniel Jachimowicz, et al.
Published: (2020-05-01)

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
by: Paul J. Bröckelmann, et al.
Published: (2022-10-01)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
by: Irene Biasoli, et al.
Published: (2023-11-01)

High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma
by: Xi Chen, et al.
Published: (2022-01-01)

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
by: Hongyu Wang, et al.
Published: (2023-03-01)